Introduction
============

Pathologic blood clots (in the form of thrombus) can result in vascular blockage which can induce serious consequences including death ([@B1]). In a healthy haemostatic system, formation of blood clots is suppressed through conversion of zymogen plasminogen (Plg) to plasmin (the serine protease that degrades fibrin) ([@B2]). However, in pathological conditions, clinical intervention through application of plasminogen activators (also known as "thrombolytic or fibrionolytic agents") to relieve the vein from thrombosis is required. Currently, routine thrombolytic agents in clinical applications are recombinant human tissue plasminogen activator (tPA), urokinase (UK) and streptokinase (SK) ([@B3]). SK unlike UK and tPA activates Plg indirectly by complex formation and in a fibrin non-specific manner ([@B4]). SK exhibits significantly higher *in vivo*half-life compared to UK and tPA, but it's fibrin non-specific mode of action and bacterial origin may increase the risk and side effects of thrombolytic therapies compared to the other two agents ([@B2]). Despite these short comings, SK gained a worldwide acceptance in developing countries due to its half-life, cost-effectiveness and shorter period of therapy ([@B3]). Moreover, a number of large-scale clinical trials, which have been conducted to compare the clinical efficacy of SK and tPA could not indicate a clear preference for either drug ([@B5]-[@B6]). Although most of the group A, C and G β-hemolytic streptococci (GAS, GCS and GGS respectively) produce and secrete SK , GCS which are neither erythrogenic toxin generators nor very fastidious in growth requirements, are the preferred bacteria for SK production ([@B7]). Historically, GCS strain *S. equisimilis*H46A (ATCC 12449) was the first streptococci to be introduced as a high-yield SK secreting bacteria (for production aims) by Christensen *et al* in 1945. Subsequently, Estrada *et al* introduced another *S. equisimilis* group C (ATCC 9542) as a SK production strain in 1992 ([@B7]). These two strains were used for SK production and served extensively as the principal source of SK gene for heterologous expression of the recombinant SK (rSK) in other hosts like *E. coli* and yeast ([@B3]).

###### 

Characteristics of the bacterial samples identified in this study

  Streptococci group   Throat culture   Genital tract   Urine culture   Skin   Blood culture   CSF   N.D   Total
  -------------------- ---------------- --------------- --------------- ------ --------------- ----- ----- -------
  GAS                  60               \-              4               1      \-              \-    \-    65
  GCS                  7                2               \-              \-     \-              \-    \-    9
  GGS                  1                \-              \-              \-     \-              \-    \-    1
  GBS                  51               20              27              3      1               3     4     109
  GDS                  19               \-              8               3      4               \-    2     36
  Staphylococcus       8                \-              \-              \-     \-              \-    3     11
  Other streptococci   16               \-              3               1      \-              \-    2     23
  Total                162              21              42              7      3               3     11    252

N.D : not determined

Due to the clinical importance and increasing potential of SK application, a great deal of effort has been directed towards improvement of quality and quantity of SK production. Most of these studies were focused on either optimization of production conditions for *S. equisimilis* H46A and 9542 , or strain development using mutant strains or protein engineering using recombinant DNA technology ([@B8]-[@B9]). Sequencing studies on the SK genes and proteins from different isolates indicated that they are heterogeneous genes ([@B10]). In fact, the sequence identity of mature SK proteins with the same number of amino acids (414 residues), ranges from 80% to 98% ([@B11]). SK heterogeneity may reflect functional diversity of the gene products in pathogenesis, antigenic variation, solubility ([@B12]), Plg activation ([@B13]) and fibrinolytic activity ([@B14]). This implies that, alternatively, it may be possible to isolate SK protein(s) with better fibrinolytic characteristics that have clinical benefits by screening among different streptococci. In this context, a number of national screening programs to isolate SK producing β-hemolytic streptococci (βHS) from local and regional samples have been conducted in different countries ([@B15]-[@B17]). However, to our best of knowledge, there is no prior report on screening and characterization of SK producing strains or recombinant expression of SK from Iranian isolated streptococci strains.

In the present study, an attempt was made for isolation and characterization of βHS among Iranian clinical isolates to screen for the best SK producing GCS strains and to clone and express the corresponding SK gene in *E. coli*, for the final aim of SK production from local and native sources.

Materials and Methods
=====================

*Bacterial strains and culturing conditions*

Two hundred and fifty two samples (initially assumed as streptococcal samples) were collected from patients with various non-invasive streptococcal diseases from different regions of Iran, during 2006 and 2010 ([Table 1](#T1){ref-type="table"}). *S. pyogenes* (GAS) ATCC 10403, *S.dysgalactiea spp.equisimilis* ATCC 9542 (GCS-9542) and *S.dysgalactiea spp.equisimilis*(GGS) CIP 55.120 (Pasteur institute of Paris) were used as reference strains for presumptive microbial, biochemical and serological tests ([Table 2](#T2){ref-type="table"}). All streptococcal isolates were cultured on 5% sheep blood agar and Todd-Hewitt Broth (THB) (Difco, USA) media. The plates were incubated at 37°C overnight. Colonies surrounded by alpha or beta-haemolysis were selected for more detailed characterization tests ([Table 2](#T2){ref-type="table"}). Presumptive standard identification tests including catalase test, susceptibility to a 0.04 U bacitracin disk and SXT disk (Sulfametoxazole 23.75µg --trimethoprim 1.25µg), CAMP test (Christie, Atkins, Munch-Petersen), PYR (Pyrolydonyl arylamidase) test, esculine hydrolysis, 6.5% NaCl tolerance and Voges- Proskauer (VP) tests were performed according to the standard protocols for determination of streptococci group A, C and G . Lancefield serotyping was performed by latex agglutination kit (Mast, UK). GCS Subspecies were further characterized by standard biochemical tests using ribose, sorbitol, lactose and trehalose fermentation ([Table 2](#T2){ref-type="table"}) ([@B18]). DH5α and M15 *E*. *coli*cells were cultured in Luria--Bertani (LB) medium. The pQE30 plasmid and M15 *E*. *coli*cells (Qiagen, USA) were used for cloning and expression of the SK gene and DH5α *E*. *coli*cells was used for propagation of plasmids. Kanamycin (50 µg/ml) was externally added to M15 *E*. *coli*culture.

###### 

Microbial and biochemical analyses undertaken for the identification of beta hemolytic streptococci in our study (adapted from ref. 18)

                            1    2    3    4      5    6    7    8      9
  ------------------------- ---- ---- ---- ------ ---- ---- ---- ------ ---------
  Haemolysis                β    β    β    β /α   β    β    β    β/ α   β /α
  Growth in 6.5% NaCl       \-   a    \-   \-     \-   \-   a    \+     a
  Growth in Bile-Aesculin   \-   \-   \-   \-     \-   \-   \-   \+     \-
  Voges-proskauer test      \-   \+   \-   \-     \-   \-   \-   \-     \+
  Pyrrolydonylarylamidase   \+   \-   \-   \-     \-   \-   \-   \+     \-
  Sensitive to bacitracin   \+   \-   v    v      \-   \-   \-   \-     \-
  H~2~O~2~ production       \-   \-   \-   \-     \-   \-   \-   \-     \-
  CAMP                      \-   \+   \-   \-     \-   \-   \-   \-     \+
  Fermentation of Ribose    \-   \+   \-   \+     v    \+   \+   \+     \-
   Sorbitol                 \-   \-   \-   v      \+   \-   \-   \-     \-
   Lactose                  \+   v    \-   \+     \+   v    v    \+     v
   Trehalose                \+   \+   \-   \+     \-   \+   \+   v      \+
  Lancefield antigen        A    B    C    C      C    C    G    D      F/C/A/G

1:*S. pyogenes*, 2:*S. agalactiae*, 3:*S. equi*, 4:*S. dysgalactiae,* 5:*S. zooepidemicus*, 6:*S. equisimilis*, 7:*S. spp.*group G (large colony variety), 8: *S. spp.*group D, 9: *S. anginosus*.

(α) Green zone around colonies on Blood Agar, (β) Clear, colourless zone around colonies on Blood Agar, (a) some strain will grow in 4% NaCl broth, (v) variable, (+) positive result, (-) negative result
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*Caseinolytic assay for streptokinase activity of bacterial culture*

Activity of streptococcal supernatant cultures was determined by caseinolytic assay([@B19]) . Briefly, 50µl of overnight culture of stains in THB was added to 5ml of fresh THB and incubated at 37°C at 150 rpm. The culture supernatants were collected by centrifugation at mid-log phase (OD~600~of 0.7-0.8) and were filtered using 0.22 µm PVDF filter (Whatman, Germany). The cell-free fluid was used to fill the pre-made wells in medium containing: 5 % skim milk and 1% agarose in sterile culturing plates. The same volume of human plasminogen (1 mg/ml) in a buffer containing: 150 mM NaCl and 50 mM Tris-HCl pH 7.4 was simultaneously added to the corresponding wells. Supernatant of*S.equisimilis* 9542 and THB were included as positive and negative controls in the corresponding wells, respectively. Plates were incubated overnight at 37°C. The clear area around the wells represented the level of SK activity of the corresponding strain.

*Isolation of the streptokinase genes and plasmid construction*

Genomic DNA of *S.equisimilis* (GCS-9542) and the selected GCS strain that showed the highest level of SK activity (GCS-S87) in caseinolytic assay ([Figure1](#F1){ref-type="fig"}) was isolated by DNA extraction kit (AxyGene, USA) and used as a template for PCR-mediated isolation of SK genes. The coding region of SK gene (lacking the signal peptide sequence) was amplified by PCR using primers with inserted restriction sites for direct cloning into pQE30 vector (forward primer; *BamH*I-SKf: 5-T[GGATCC]{.ul}ATTGCTGGACCTGAGTGG CTG-3; reverse primer;*Pst*I-SKr: 5-CG[CCGCAG]{.ul}TTATTTGTCGTTAGGGTTATC, the sequences corresponding to restriction sites are underlined). The resulting amplified fragments were digested with *BamH*I and *Pst*I and cloned into the same sites of pQE30 expression vector in tandem with the fused N-terminally 6XHis-tag and downstream of T5 promoter ([Figure 2](#F2){ref-type="fig"}). Proper expression constructs were confirmed by restriction enzyme analysis and bidirectional sequencing. All cloning steps were performed according to standard procedures ([@B20]).

*Protein expression in E. coli*

*E. coli* M15 cells, which carry multiple copies of pREP4 plasmid that tightly regulate recombinant protein expression ([@B21]) were used as an expression host for pQE30 plasmids according to the manufacturer's protocol (Qiagen,USA). Briefly, after transformation of bacterial cells with the recombinant plasmids pSK9542 and pSK87 using the standard CaCl~2~ method ([@B20]), expression of the target fusion protein was induced at OD~600~ of 0.5--0.6 by isopropyl-β-D-thio-galactoside (IPTG) to a final concentration of 0.5 mM. Cells were harvested by centrifugation after 6 hours of incubation at 37°C and stored at -20°C for purification steps.
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*Purification and refolding of expressed SK*

The His6-SK fusion proteins were purified by nickel affinity chromatography under denaturing conditions according to the manufacturer's protocol (Qiagen,USA). The pellet was dissolved in denaturing binding buffer (8 M Urea, 100 mM NaH~2~PO~4~, 100 mM Tris-Cl pH 8.0) and supernatant of the solubilized suspension after centrifugation was loaded onto Ni--NTA agarose resin. After washing steps, the fusion proteins were eluted with the elution buffer (8 M Urea, 100 mM NaH~2~PO~4~, 100 mM Tris-Cl t pH 4.5). The eluted proteins were refolded via dialysis in refolding buffer (20mM Tris-HCl pH7.4 and 10% Glycerol). Polyethylene Glycol (PEG) 20000 was used for protein concentration according to standard procedures ([@B22]). The protein concentration was determined by standard Bradford assay and optical density at 280nm (OD~280~).

*SDS-PAGE and Western blot analyses of rSK*

SDS--polyacrylamide gel electrophoresis was performed for protein expression assay. For western blotting, proteins were transferred to nitrocellulose membrane and the membrane was blocked by 5% BSA. Mouse anti-penta His monoclonal antibody (Qiagen, USA) was used as the primary antibody and goat anti-mouse IgG conjugated to HRP (Horse Radish peroxidase) (Qiagen,USA) as the secondary (tracking) antibody .The bound antibodies were detected using 3, 3- Diaminobenzidine (DAB) (Qiagen, USA).

*Chromogenic assay of purified rSK activity*

SK activity was determined by chromogenic substrate as previously described ([@B23]). Purified rSK (5nM) was added to a microtiter plate containing 0.2 mM of chromogenic substrate S-2251 (H-D-valyl-L-leucyl-L-lysine-p-nitroanilide dihydrochloride; Sigma, USA) and 200 nM of human plasminogen (Sigma,USA) at 37 °C in a total volume of 100 µl of assay buffer (50 mM Tris-HCl, 150 mM NaCl, pH 7.4). Hydrolysis of S-2251 was measured at 405 nm every 5 min for 60 min in a microplate reader (BioHIT, UK). The protein activity was calculated using standard activity curve of streptase^®^ (CSL, Behring, Germany).

Results
=======

*Screening of β-haemolytic streptococci (βHS) and isolation of SK producing GCS*

A total of 252 samples ([Table 1](#T1){ref-type="table"}) were examined by microbiological and biochemical assays ([Table2](#T2){ref-type="table"}). βHS including group A, C and G were found in 75 out of 250 streptococci specimens (29.4%). Group A was the dominant Lancefield serogroup found in 65 out of 250 streptococci specimens (25.8%) followed by GCS (9 out of 250; 3.6%) and GGS (1 out of 250; 0.4%), respectively. Throat culture was the common source of GAS (60 out of 250 isolates), followed by urine culture (4 out of 250 isolates) and soft tissue (1 out of 250 isolates). GCS were less common and were totally isolated from respiratory tract (7 out of 250 isolates) and genital tract (2 out of 250 isolates). More detailed fermentation analyses on isolated GCS ([Table 2](#T2){ref-type="table"}) could determine eight *S. dysgalactiae* subsp. *equisimilis* strains and one strain of *S.dysgalactiae* subsp. *dysgalactiae*([Table 3](#T3){ref-type="table"}; sample codes are based on in house coding). Most of GCS isolates showed low to moderate SK activity in caseinolysis assay, except for GCS-S87 that showed predominant SK activity compared to the reference strain (GCS-9542) and thus was selected for further cloning studies ([Figure 1](#F1){ref-type="fig"}).

###### 

Distribution of identified GCS subspecies in different samples

  No.   Sample No.   culture Source   Disease                     Sub species of GCS
  ----- ------------ ---------------- --------------------------- --------------------
  1     S-04         Human throat     Streptococcal pharyngitis   *S.equisimilis*
  2     S-05         Human throat     Streptococcal pharyngitis   *S.equisimilis*
  3     S-08         Human vagina     Puerperal fever             *S.equisimilis*
  4     S-87         Human throat     Streptococcal pharyngitis   *S.equisimilis*
  5     S-91         Human throat     Acute tonsillitis           *S.dysgalactiae*
  6     S-131        Human vagina     Puerperal fever             *S.equisimilis*
  7     K-17         Human throat     Acute tonsillitis           *S.equisimilis*
  8     K-19         Human throat     Acute tonsillitis           *S.equisimilis*
  9     K-34         Human throat     Acute tonsillitis           *S.equisimilis*
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*Cloning, expression, purification and refolding of the rSK*

Using the SKf and SKr primers and genomic DNA of *S.equisimilis* GCS-9542 and *S.equisimilis* GCS-S87 as template, PCR reactions resulted in a single band of the expected length (1242bp) of SK gene for both strains ([Figure 3](#F3){ref-type="fig"}). Cloning steps for insertion of SK gene in pQE30 vector is illustrated ([Figure 2](#F2){ref-type="fig"}). Restriction enzyme analyses of the recombinant vector harboring SK gene (pSK87) ([Figure 3](#F3){ref-type="fig"}) and nucleotide sequence analyses (not shown) confirmed the accuracy of cloning procedures.

Expression of pSKC plasmids produced rSK with a predicted molecular mass of about 47 kDa, harboring a 6XHis domain which was appended to the N- terminus of the native molecule. Crystal structure of streptokinase shows that the N-terminal of the enzyme is unfolded ([@B24]), thus, addition of polyhistidine at the NH~2~-terminus of the enzyme was expected to have little or no effect on the catalytic activity. Analysis of protein profile of un-induced and induced cell lysates on SDS-PAGE proved expression of SK by both strains ([Figure 4A](#F4){ref-type="fig"}). Analysis of the purified rSK further indicated two major bands on the gel ([Figure4A](#F4){ref-type="fig"}). The upper band which was the most prominent protein corresponded to the full length SK (47 kDa) and the lower band (around 44 kDa) might be related to the digested form of SK as previously suggested ([@B25]). Accordingly, the eluted (purified) recombinant proteins were identified by the presence of the same two bands in western blot analysis ([Figure 4B](#F4){ref-type="fig"}). Evaluation of the expression efficiencies for the rSK proteins by concentration measurements at OD~280~ and Bradford assay indicated yields of 0.53 mg/ml (rSK9542) and 0.59 mg/ml (rSKS87) for the purified proteins.

*Biological activity assay of streptokinase by chromogenic method*

The chromogenic assay in the absence of fibrin is known as an approved an internationally standard assay for streptokinase activity (Third International Standard for streptokinase; National Institute of Biological Standard and Controls, NIBSC, 2004UK) ([@B26]). Employing this method and chromogenic substrate S-2251, a standard curve based on definite activity of Streptase^®^ was plotted (Data not shown). Subsequently, the biological activity (which represents the activity of SK in International Units per ml of total volume; IU/ml) and specific activity (which refers to the activity of rSK per mg of total protein; IU/mg) were calculated based on the plotted standard curve. The calculated values for the biological activities were 11200 IU/ml (rSK9542) and 10720 IU/ml (rSKS87) and for specific activities were 0.21x10^5^ IU/mg (rSK9542) and 0.18x10^5^ IU/mg (rSKS87).
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